SCHEMBL5648385

SCHEMBL5648385

CCNC(=O)COc1ccc(Cl)cc1CNC(=O)Cc1c(C)ccn(NCc2nccn2C)c1=O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
F2 P00734 12/20 0.51
PRSS1 P07477 7/20 0.51
PRSS2 P07478 7/20 0.51
PRSS3 P35030 7/20 0.51
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 3/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ANO1 Q5XXA6 1/20 0.40
ANO2 Q9NQ90 1/20 0.40
P2RX7 Q99572 2/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GLA P06280 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650131 0.87 F2 (0.52) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL5650277 0.86 F2 (0.51) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL5650866 0.86 F2 (0.51) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL5651509 0.86 F2 (0.54) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL5652203 0.86 F2 (0.52) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL5646063 0.86 F2 (0.52) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL5652489 0.85 F2 (0.52) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL5650742 0.85 F2 (0.51) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL5647387 0.85 F2 (0.44) F2PRSS1CYP3A4P2RX7
SCHEMBL5651304 0.85 F2 (0.50) F2PRSS1PRSS2PRSS3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161643-A1 Pyridin-2-one compounds useful as inhibitors of thrombin ASTRAZENECA AB (SE) 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161643-A1 Pyridin-2-one compounds useful as inhibitors of thrombin PLG, F2, PLAT F2 2/4885PRSS1 20/4885PRSS2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.